MDCO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MDCO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-11), The Medicines Co's share price is $84.90. The Medicines Co's Book Value per Share for the quarter that ended in Sep. 2019 was $-0.33. Hence, The Medicines Co's PB Ratio of today is .
The historical rank and industry rank for The Medicines Co's PB Ratio or its related term are showing as below:
The historical data trend for The Medicines Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Medicines Co Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
PB Ratio | Get a 7-Day Free Trial | 1.97 | 3.47 | 3.69 | 80.41 | - |
The Medicines Co Quarterly Data | ||||||||||||||||||||
Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
PB Ratio | Get a 7-Day Free Trial | - | - | - | 75.82 | - |
For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where The Medicines Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
The Medicines Co's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Sep. 2019) |
= | 84.90 | / | -0.327 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The Medicines Co (NAS:MDCO) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of The Medicines Co's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander J Denner | director | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Peter Wijngaard | officer: Chief Development Officer | 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Paris Panayiotopoulos | director | ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Geno J Germano | director | 5 GIRALDA FARMS, MADISON NJ 07940 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Christopher T Cox | officer: EVP & Chief Corp. Dev. Officer | CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281 |
Fredric N Eshelman | director, officer: Executive Chairman | PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Armin M Kessler | director | |
Robert J Hugin | director | C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054 |
Hiroaki Shigeta | director | THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Stuart A Kingsley | officer: President and COO | 152 CHESTNUT STREET, WEST NEWTON MA 02465 |
Robert G. Savage | director | C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591 |
Glenn Sblendorio | director, officer: President & CFO | 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
James E Flynn | 10 percent owner, other: Possible Members of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Management Company, L.p. (series C) | 10 percent owner, other: Possible Members of 10% Group | 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
From GuruFocus
By gurufocus 10qk • 05-10-2010
By PRNewswire PRNewswire • 05-20-2019
By Sydnee Gatewood Sydnee Gatewood • 02-03-2020
By PRNewswire PRNewswire • 12-31-2019
By gurufocus 10qk • 11-10-2009
By Holly LaFon Holly LaFon • 07-17-2019
By Marketwired Marketwired • 12-10-2019
By PRNewswire PRNewswire • 12-03-2019
By Marketwired Marketwired • 12-04-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.